Systemic vascular resistance during brief withdrawal of angiotensin converting enzyme inhibition in heart failure
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Systemic vascular resistance during brief withdrawal of angiotensin converting enzyme inhibition in heart failure. / Gabrielsen, A; Bie, P; Christensen, N J; Frandsen, E; Galatius, S; Pump, B; Sørensen, V B; Kastrup, J; Norsk, P.
In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 62, No. 4, 01.01.2002, p. 245-54.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Systemic vascular resistance during brief withdrawal of angiotensin converting enzyme inhibition in heart failure
AU - Gabrielsen, A
AU - Bie, P
AU - Christensen, N J
AU - Frandsen, E
AU - Galatius, S
AU - Pump, B
AU - Sørensen, V B
AU - Kastrup, J
AU - Norsk, P
PY - 2002/1/1
Y1 - 2002/1/1
N2 - We tested the hypothesis that moderate increases in endogenous angiotensin II (Ang II) concentrations, induced by withdrawal of angiotensin converting enzyme inhibition (ACE-I) in patients with compensated heart failure (HF) on chronic medical therapy, do not increase or impair control of systemic vascular resistance (SVR). SVR was determined in supine and seated positions in 12 HF patients [NYHA class II-III; ejection fraction=0.29 +/- 0.03 (mean +/- SE)] and 9 control subjects. HF patients were investigated during high (n=11; withdrawal of ACE-I treatment for 24 h) and low (n=9; sustained ACE-I therapy) endogenous plasma Ang II concentrations. Withdrawal of ACE-I therapy in HF caused moderately increased Ang II concentrations of 30 +/- 5 pg/ml compared with 12 +/- 2 pg/ml in controls (p
AB - We tested the hypothesis that moderate increases in endogenous angiotensin II (Ang II) concentrations, induced by withdrawal of angiotensin converting enzyme inhibition (ACE-I) in patients with compensated heart failure (HF) on chronic medical therapy, do not increase or impair control of systemic vascular resistance (SVR). SVR was determined in supine and seated positions in 12 HF patients [NYHA class II-III; ejection fraction=0.29 +/- 0.03 (mean +/- SE)] and 9 control subjects. HF patients were investigated during high (n=11; withdrawal of ACE-I treatment for 24 h) and low (n=9; sustained ACE-I therapy) endogenous plasma Ang II concentrations. Withdrawal of ACE-I therapy in HF caused moderately increased Ang II concentrations of 30 +/- 5 pg/ml compared with 12 +/- 2 pg/ml in controls (p
KW - Angiotensin-Converting Enzyme Inhibitors
KW - Baroreflex
KW - Blood Pressure
KW - Cardiac Output
KW - Heart Failure
KW - Humans
KW - Male
KW - Middle Aged
KW - Posture
KW - Substance Withdrawal Syndrome
KW - Sympathetic Nervous System
KW - Vascular Resistance
M3 - Journal article
C2 - 12476922
VL - 62
SP - 245
EP - 254
JO - Scandinavian Journal of Clinical & Laboratory Investigation
JF - Scandinavian Journal of Clinical & Laboratory Investigation
SN - 0036-5513
IS - 4
ER -
ID: 33967768